# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-022194
Filing Date
2024-05-09
Accepted
2024-05-09 16:04:01
Documents
67
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sgmo-20240331.htm iXBRL | 10-Q | 915453
2 | EX-10.1 | secondamendmenttoleaseag.htm | EX-10.1 | 17866
3 | EX-31.1 | sgmo-20240331xex311.htm | EX-31.1 | 10017
4 | EX-31.2 | sgmo-20240331xex312.htm | EX-31.2 | 10132
5 | EX-32.1 | sgmo-20240331xex321.htm | EX-32.1 | 7126
11 | GRAPHIC | secondamendmenttoleaseag001.jpg | GRAPHIC | 244063
12 | GRAPHIC | secondamendmenttoleaseag002.jpg | GRAPHIC | 311423
13 | GRAPHIC | secondamendmenttoleaseag003.jpg | GRAPHIC | 316673
14 | GRAPHIC | secondamendmenttoleaseag004.jpg | GRAPHIC | 262478
15 | GRAPHIC | secondamendmenttoleaseag005.jpg | GRAPHIC | 84834
16 | GRAPHIC | secondamendmenttoleaseag006.jpg | GRAPHIC | 58043
| Complete submission text file | 0001628280-24-022194.txt |  | 7093284

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | sgmo-20240331.xsd | EX-101.SCH | 40460
7 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | sgmo-20240331_cal.xml | EX-101.CAL | 58367
8 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | sgmo-20240331_def.xml | EX-101.DEF | 214978
9 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | sgmo-20240331_lab.xml | EX-101.LAB | 437857
10 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | sgmo-20240331_pre.xml | EX-101.PRE | 320325
71 | EXTRACTED XBRL INSTANCE DOCUMENT | sgmo-20240331_htm.xml | XML | 720865

Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30171 | Film No.: 24930361
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)